By Digital Spartans 
Selmore Pharmaceuticals Ltd., a Pakistan-based veterinary pharmaceutical company, is preparing to raise around Rs. 2 billion through an initial public offering (IPO) as it seeks a listing on the Main Board of the Pakistan Stock Exchange (PSX).
The exchange has published the company’s draft prospectus for public review, marking an important step in Selmore Pharmaceuticals’ proposed entry into the listed capital market.
According to the draft prospectus, the IPO will comprise 48.61 million ordinary shares. The shares have been offered at a floor price of Rs. 42 per share, putting the potential value of the offering at approximately Rs. 2.04 billion.
The PSX has invited members of the public and other stakeholders to submit comments on the draft prospectus. The deadline for submitting feedback is October 5, 2026.
Selmore Pharmaceuticals operates in the veterinary medicines sector and has developed a business focused on products serving Pakistan’s livestock and poultry industries. Its proposed listing would add another pharmaceutical-sector company to the publicly traded market.
The company has also established an international export presence, supplying products to a number of markets across Asia, the Middle East, Africa and other regions.
Its export footprint includes Afghanistan, Kazakhstan, South Korea, Kuwait, Nepal, Nigeria, Oman, Qatar and Saudi Arabia. The company also has a presence in markets including Syria, Lebanon, Jordan, Iraq, Iran, Chad, Peru and Vietnam.
Selmore’s sales profile is strongly linked to the livestock sector. During the first nine months of fiscal year 2026, livestock-related products accounted for 64.8 percent of the company’s total sales.
The poultry segment represented the remaining 35.2 percent of sales during the same period, highlighting the company’s focus on two major segments of the veterinary pharmaceutical market.
The proposed IPO could provide Selmore Pharmaceuticals with access to Pakistan’s capital market and a broader base of investors. A listing on the PSX Main Board would also subject the company to the disclosure and regulatory requirements applicable to listed companies.
The draft prospectus gives prospective investors and market participants an opportunity to review information about the company and its proposed share offering before the IPO process advances further.
The Rs. 42 floor price will be an important reference point for investors assessing the proposed offering. However, the final terms and other details of the transaction will depend on the completion of the applicable regulatory and listing process.
The company’s established export network is another notable feature of the proposed listing. Its presence across multiple international markets provides Selmore with exposure beyond Pakistan’s domestic veterinary pharmaceutical market.
With the public-comment period scheduled to remain open until October 5, the next stages of the IPO process will depend on regulatory requirements and the company’s progress toward completing its planned listing.
If approved and completed, Selmore Pharmaceuticals’ offering would bring a veterinary-focused pharmaceutical business to the PSX Main Board while giving investors an opportunity to participate in a company serving Pakistan’s livestock and poultry sectors as well as international markets.